Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment-Reference-Cited by-同舟云学术

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment

Published:2017-06-15 Issue:11 Volume:57 Page:1425-1431
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Guérard Nicolas¹,Zwingelstein Christian¹,Dingemanse Jasper¹

Affiliation:

1. Department of Clinical Pharmacology; Actelion Pharmaceuticals Ltd; 4123 Allschwil Switzerland

Funder

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. Fabry disease;Thomas;Pediatr Endocrinol Rev,2014

2. Fabry disease;Germain;Orphanet J Rare Dis,2010

3. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females;MacDermot;J Med Genet,2001

4. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males;MacDermot;J Med Genet,2001

5. Fabry disease;Schiffmann;Pharmacol Ther,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers;Clinical Drug Investigation;2024-05-02

2. Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease;Clinical Pharmacology in Drug Development;2024-02-16

3. PEG-Capped Ceria–Zirconia Nanoparticles Improved Renal Fibrosis In Cellular and Animal Models of Fabry Disease;ACS Applied Nano Materials;2024-01-16

4. Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review;Current Neuropharmacology;2023-03

5. Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021;Brazilian Journal of Nephrology;2022-06